论文部分内容阅读
目的 观察阿托伐他汀对冠心病并慢性心衰（CHF）患者高敏C反应蛋白（hsCRP）、高敏心肌肌钙蛋白T（hs‐cTnT）水平及预后的影响。方法 将100例冠心病并CHF患者随机分为对照组和观察组各50例。对照组予常规抗心衰治疗，观察组在常规治疗的基础上加用阿托伐他汀（20 mg／d）。两组患者治疗前及治疗后1个月均检测hsCRP、hs‐cTnT。治疗后1年随访，记录主要心血管不良事件（MACE）发生率及心衰再住院率。结果 ①治疗1个月后，观察组较对照组hsCRP、hs‐cTnT 下降更明显[（3．02±0．53） mg／L与（3．88±0．64） mg／L ，P＜0．05；（0．018±0．009） ng／mL与（0．029 ± 0．008） ng／mL ，P＜0．05）]；②随访1年内，观察组较对照组MACE率及心衰再住院率均更低（15．6％与21．7％，P ＜0．05；26．7％与37．0％，P ＜0．05）。结论 阿托伐他汀治疗可降低冠心病并CHF患者炎症因子水平、心肌损伤程度，并改善其预后。“,”Objective]To observe the effect of atorvastatin on the levels of hypersensitive C‐reactive pro‐tein(hsCRP) ,hypersensitive cardiac troponin T (hs‐cTnT ) and the prognosis in patients with coronary heart diease(CHD) and chronic heart failure(CHF) .[Methods]Totally 100 patients with CHD and CHF were ran‐domly divided into observation group( n=50) and control group( n =50) .The control group was given con‐ventional medication of anti‐heart failure strategies ,while the observation group received additional atorvasta‐tin 20mg daily based on the conventional treatment .hsCRP and hs‐cTnT were determined before and after 1 month of treatment .The incidence of major adverse cardiovascular events(MACE) and rehospitalization rate were recorded during 1‐year follow up after treatment .[Results]Compared with control group ,the levels of hsCRP and hs‐cTnT in observation group were decreased more significantly after treatment for 1 month[(3 .02 ± 0 .53)mg/L vs .(3 .88 ± 0 .64)mg/L ,(0 .018 ± 0 .009)ng/mL vs .(0 .029 ± 0 .008)ng/mL ,both P<0 .05] . Compared with control group ,MACE and rehospitalization rate in observation group during 1‐year follow up were even decreased[15 .6% vs .21 .7% ,26 .7% vs .37 .0% ,both P<0 .05] .[Conclusion]Atorvastatin can reduce the levels of inflammatory factors and myocardial injury ,and improve the prognosis of patients with CHD and CHF .